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A 56 year old woman presented with pelvic discomfort. Ultra-
sound revealed a 10 cm complex right adnexal mass. The CA-125
was 134. Laparotomy revealed high grade clear cell carcinoma of⁎ Corresponding author.
E-mail address: aalok.kumar@medportal.ca (A. Kumar).
Fig. 1. A. The ovarian tumor, showing typical clear cell carcinoma, composed of an admixture o
Bone biopsy, showing metastatic clear cell carcinoma, morphologically identical to that seen in
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Open access under CC BY-NC-SA license.the right ovary (OCCC) only, without surface involvement but with
positive ascitic ﬂuid and no extra-ovarian spread, FIGO stage IC
(Fig. 1A).
Subsequent left lumbosacral pain developed, radiating to the left but-
tock, thigh and leg. A bone scan revealed a solitary focus of increased up-
take in the intertrochanteric region of the proximal left femur (Fig. 2A),
with metastasis suspected. Correlative poorly marginated osteosclerosis
was subsequently identiﬁed on radiography. There was no osteolysis or
fracture. These ﬁndings were conﬁrmed on CT, with no evidence of cor-
tical disruption. The lesion demonstrated medullary T1 hypointensity
and STIR hyperintensity onMR,with no associated soft tissuemass.Max-
imal dimensions were 4.2 × 2.6 × 7.0 cm craniocaudal, with additional
lobules of involvement extending into the metadiaphysis. These ﬁnd-
ings of inﬁltrative disease were consistent with metastasis, and less
likely primary neoplasia. A core biopsy of the left proximal femur subse-
quently conﬁrmed the presence of metastatic ovarian carcinoma of
OCCC histology (Fig. 1B). This metastasis was also visualized on 18F-
FDG PET/CT (Fig. 2B), which also revealed regions of increased activity
in the left sacrum and right ilium.
The patient had received 3 cycles of carboplatin and paclitaxel by
the time of the bone biopsy. The chemotherapy did not treat the bone
involvement. Subsequent irradiation to the left hip and sacroiliac regionf clear cells and cells with eosinophilic cytoplasm, with malignant cytological features. B.
the ovary.
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4 more cycles of carboplatinum and paclitaxel chemotherapy. A follow-
up 18F-FDG-PET scan revealed progressionwith new areas of disease in
the thoracic spine and right sacroiliac region. The previously irradiated
area of the left femur however had “interval metabolic response to
treatment with only minimal residual FDG accumulation persisting”
(Fig. 2C).
Case series
Our belief was that bone metastases are more commonly observed
among OCCC than with the high grade serous histology (HGSC). ToFig. 2.A. Initialwhole body bone scandemonstrating a single abnormality of the let proximal fem
radiation demonstrating response.conﬁrm this, institutional Research Ethics Board approval was obtained
to review the initial metastatic pattern of all OCCC diagnosed and treat-
ed at one of the British Columbia Cancer Agency (BCCA) centers be-
tween 2000 and 2008 and to compare them to an equal number of
randomly selected cases of HGSC, diagnosed during the same time peri-
od. The BCCA treats approximately 2/3 of all patients with a diagnosed
malignancy in the province (population 4.5 million people). We identi-
ﬁed 52 cases of OCCCwith recurrence and matched themwith 50 cases
of HGSC. At diagnosis, 24 of 52 cases of OCCC had stages IA–IIC disease,
and the remainder had stages IIIA–C (including residual positive dis-
ease). Thirty nine of 50 HGSC patients had FIGO stage IIIC, and 11 pa-
tients had stages IB to IIIB. Imaging was obtained on 49/50 and 50/52ur. B. Initial PET scan demonstrating cancer involvement of the left femur. C. PET scanpost
Table 1
Rate of hematogenous metastases among OCCC and HGSC of the ovary.
Histology Hematogenous only
(% of total cases)
Bone metastases
(% of total cases)
Other (% of total cases)
OCCC 10 (25) 3 (6) 41 (79)
High grade serous 8 (13) 0 (0)a 42 (78)
a One case had vertebral bone involvement from direct extension of ametastatic lymph
node.
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primarily in the form of CT of the abdomen and pelvis. The median
age at diagnosis was 53 years (range 24–88 years) and 64 years
(range 36–84 years) for the OCCC and HGSC cases, respectively. The
median time to relapse (fromdiagnosis to recurrence)was 12.7 months
and 17.1 months for OCCC and HGCS, respectively.
Thirteen of 52 (25%) patients with recurrent OCCC had evidence of
hematogenous metastases (i.e. visceral organ or bone disease). Three
of these patients had distant bone metastases. Two of the patients
with painful bone lesions required additional investigation with dedi-
cated bone imaging. The third patient was found to have bonemetasta-
ses incidentally at the time of relapse in other areas. Among the patients
with recurrent high grade serous type, 8 of 54 (15%) had hematogenous
metastatic disease, the majority to the liver (6 patients). One case of
high grade serous cancer had vertebral bone involvement due to direct
disease extension of a malignant retroperitoneal lymph node. No cases
of brain metastases were recorded in either group (Table 1).
Discussion
The occurrence of bonemetastases at any time is rare in ovarian can-
cers, reported in b2% of cases (Sugiyama et al., 2000), hence dedicated
bone imaging is not routinely used. Our case report is interesting, as
bone metastases at the time of OCCC diagnosis is rarely observed
(Sugiyama et al., 2000). Itwas also interesting in that the classic ﬁndings
of bone metastases (lytic lesions on X-ray or CT scan) were not appar-
ent. Finally, despite apparent early stage disease, hematogenous spread
had already occurred. Our patient may have been at risk for this given
that cytologic positivity is known to be an adverse predictive factor for
relapse (Hoskins et al., 2012).
Patterns ofmetastases inOCCC have not beenwell described. There is
a single retrospective review of 44 cases of OCCC from the BrighamHos-
pital (spanning 1944 to 1981) in the literature. Of 25 patients who had
recurrence, 40% had distant organ involvement which included bone,
breast and brain (Montag et al., 1989). These were compared with a
matched cohort of 55 patients with HGSC. Lymph node involvement
was much more common among the patients with OCCC (40% vs. 7%)
as was visceral organ involvement (40% vs. 13%). There were no cases
of bone metastases among the HGSC patients compared to 16% among
the clear cell cases (Jenison et al., 1989). This is in keeping with prior re-
ports that bone metastases in HGSC are rare (Pectasides et al., 2006).
This observational case series suggests that bona ﬁde hematogenous
bone metastasis, while rare, is more likely to occur in OCCC than HGSC.
Our analysis was not powered for statistical comparisons. While we did
not record all sites of metastases throughout the full disease course, our
initial observations are in keeping with clinical experience. Given that
restaging with CT scans at the time of suspected relapse was the main
imagingmodality used in both the OCCC andHGSC patients, it is unlike-
ly that a bias in detecting bone metastases exists. 2 of the 3 cases with
bonemetastases were investigated for pain as the presenting symptom
while the other patient on staging CT was found to have a suspicious
bone lesion prompting further investigations.
Our case is typical, in that the beneﬁts of systemic therapyweremin-
imal. However, the palliative beneﬁt of radiationwas both clinically and
radiologically apparent. Advanced OCCC has a low response rate to
standard cytotoxic regimens and a poorer prognosis than the HGSCcounterpart (Recio et al., 1996). A series by Sugiyama et al. (2000)
showed an 11.1% response rate with the use of platinum based regi-
mens. Radiation therapy may have an under-recognized role in the
management of OCCC (Nagai et al., 2007) (Swenerton et al., 2011). In
a review of 158 women with advanced OCCC, 14 received radiation
therapy alone for relapse. Treatment beneﬁt was seen in 64% compared
to 24% of the remainder receiving chemotherapy alone (Al-Barrak et al.,
2011). The choice of chemotherapy administered did not have an im-
pact. A beneﬁcial impact of radiation on survival was also suggested in
a large, population-based cohort of early stage patientswithOCCC treat-
ed adjuvantly with chemotherapy and radiation (Hoskins et al., 2012).
Ovarian carcinomas are represented by a number ofmolecularly dis-
tinct diseases broadly deﬁned by histotype, with different outcomes,
patterns of relapse and response to therapy (Kobel et al., 2008). Clini-
cians treating patientswithOCCCneed to be aware of themetastatic po-
tential of this disease and investigate symptomatic patients accordingly.
Radiotherapy may be an effective treatment modality, even in the set-
ting of otherwise chemotherapy refractory disease.Conﬂict of interest
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